Clinical trials: for Brain Tumors
Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV)
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
This is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an…
- Conditions
- Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV), Brain Tumor Recurrent, Brain Tumor Adult
- Trial name
- NCT04988750
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- NaviFUS Corporation
Brain Neoplasm
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
This study is planned to detect a dose-efficacy relationship between the chosen dose levels of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with newly diagnosed malignant glioma.
- Trial name
- NCT02755142
- Testing
- Gliolan
- Volunteers
- 21 people
- Sponsor
- medac GmbH
Glioblastoma or Gliosarcoma
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant primary brain tumor in adults and can be resistant to conventional therapies.
- Trial name
- TARGET-I (NCT02197169)
- Testing
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Frozen Sections, Indocyanine Green
Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.
The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an…
- Conditions
- Frozen Sections, Indocyanine Green, Brain Tumor
- Trial name
- PRECISION (NCT06867978)
- Testing
- cCeLL In vivo, Indocyanine Green
- Volunteers
- 100 people
- Sponsor
- VPIX Medical
Craniotomy for Epilepsy and Malignant Tumor Removal
Brain-Shift Monitoring Using 3D Scanning
A prospective non-invasive data/image collection for evaluation of the performance of the Advanced Scanners 3D scanner during brain surgery.
- Trial name
- NCT05018338
- Testing
- Brain shift monitoring
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Advanced Scanners Inc.
Cancer, Neurological Disorder
Bolus Pouch Feed Study
The primary aim of this study is to evaluate the impact of introducing a new enteral tube feed on health and feeding related quality of life.
- Conditions
- Cancer, Neurological Disorder, Gastrointestinal Dysfunction, Oral Complication
- Trial name
- NCT05822557
- Testing
- Bolus Pouch Feed
- Where
- 15 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Nutricia UK Ltd
Recurrent Glioblastoma
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model 4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with recurrent glioblastoma (rGBM) undergoing…
- Trial name
- NCT04417088
- Testing
- Carboplatin, Exablate BBBD
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- InSightec
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Neoplastic Disease, Glioblastoma
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of…
- Conditions
- Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform
- Trial name
- IPAX BrIGHT (NCT07100730)
- Testing
- TLX-101-Tx + Lomustine, TLX101-Tx
- Where
- 9 sites in Australia, Austria and 2 more
- Volunteers
- 50 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Brain Tumor
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric…
- Trial name
- NCT05630209
- Testing
- Exablate, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- InSightec
Glioma (Any Grade) in the Brain
18F-Floretyrosine Expanded Access Program
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to…
- Trial name
- NCT06743100
- Testing
- 18F-Floretyrosine
- Where
- 10 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Epilepsy; Seizure
ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors
Phase 2A single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and…
- Trial name
- NCT04737174
- Testing
- ES-481
- Sponsor
- ES Therapeutics Australia Pty Ltd
Progressive Pediatric Brain Cancer
Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer
This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in…
- Trial name
- NCT07732413
- Testing
- NLG802 (indoximod Prodrug), Temozolomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lumos Pharma
Glioblastoma, Squamous Cell Carcinoma
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.
- Conditions
- Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT05974410
- Testing
- AVM0703, Hydrocortisone, Proton pump inhibitor
- Sponsor
- AVM Biotechnology Inc
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Peritumoral Brain Edema, PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS
Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)
This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors.
- Trial name
- NCT00691522
- Testing
- Xerecept
- Volunteers
- 60 people
- Sponsor
- PharmaNet
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
Parkinson's Disease
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
The purpose of this study is to determine the safety and efficacy of AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain.
- Trial name
- NCT00643890
- Testing
- Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Neurologix, Inc.
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC